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From the Cochrane Musculoskeletal Group
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GEORGE A. WELLS, PETER S. TUGWELL, and MAARTEN BOERS
ABSTRACT. Objective. To assess the quality of reporting in Cochrane musculoskeletal systematic reviews
(excluding back and injury reviews).
Methods. This study assessed all the Cochrane Musculoskeletal Group’s systematic reviews from
Issue 4, 2002, of the Cochrane Library Database of Systematic Reviews. Two reviewers independ-
ently extracted data and assessed quality. Two assessment tools were used, including an 18 item
checklist and flow chart developed by the Quality of Reporting of Meta-analysis (QUOROM) con-
sensus group, and a 10 item scale, the Oxman-Guyatt Overview Quality Assessment Questionnaire
(OQAQ). One question on the latter scale (item 10) scores overall quality on a 7 point scale, with
high scores indicating superior quality. Data were analyzed using univariate approaches.
Results. The 57 systematic reviews assessed were found to have good overall quality, with scores on
individual items revealing only minor flaws. Documenting the flow of included and excluded stud-
ies and summarizing the results are 2 areas needing improvement in reporting. According to the
Oxman-Guyatt scale the overall scientific quality of the Cochrane musculoskeletal reviews was good
[mean 5.02 (95% CI 3.71–6.32)].
Conclusion. Our study found that the reporting quality of Cochrane musculoskeletal systematic
reviews was generally good, although there was room for improvement. For example, it might be
feasible to develop specific guidelines for reporting protocols. Certainly more work is needed in
reporting search results, documentation of the flow of studies, identification of the type of studies,
and summarization of the key findings. (J Rheumatol  2006;33:9-15; First Release: Nov 1, 2005)
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It has been estimated that a physician would need to read
17–20 journal articles a day to keep abreast of all research
relevant to a particular area of clinical practice1. Because this
is clearly impractical, interest has been growing in the use of
pre-appraised and synthesized evidence resources such as
systematic reviews, metaanalyses, and evidence-based clin-
ical practice guidelines as aids to clinical decision-making.
Recognition of the need for systematic reviews of health-
care studies continues to grow and is indicated by the num-
ber of articles and empirical studies dealing with methods
used in reviews, the number of systematic reviews published
in healthcare journals, and the rapid growth of the Cochrane
Collaboration2-4. The Cochrane Library is a compilation of
systematic reviews designed to provide high quality scien-
tific evidence on the effectiveness of various healthcare
interventions5. Cochrane reviews serve an invaluable func-
tion by summarizing healthcare literature and supporting
decisions for more effective clinical practices. The
Cochrane Musculoskeletal Group (CMSG) is one of more
than 50 entities within the Cochrane Collaboration. Its
members are dedicated to preparing and maintaining sys-
tematic reviews of musculoskeletal conditions. Many inter-
ventions for gout, lupus erythematosus, osteoarthritis, osteo-
porosis, rheumatoid arthritis, soft tissue conditions, spondy-
loarthropathy, systemic sclerosis, and vasculitis have been
reviewed. Separate review groups study reviews of back and
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musculoskeletal injuries. We assessed the quality of reviews
conducted by the CMSG.
Growing recognition of the key role of reviews in syn-
thesizing and disseminating research results has prompted
careful scrutiny of the validity of reviews. In the 1970s and
early 1980s, psychologists and social scientists drew atten-
tion to the systematic steps needed to minimize bias and ran-
dom errors in literature reviews6-9. In the late 1980s atten-
tion began to focus on the poor scientific quality of health-
care review articles10,11.
An appreciation of the quality of a systematic review is
essential to assessment of whether its recommendation of
the use or avoidance of an intervention should be fol-
lowed12,13. Two major areas are assessed in determining the
quality of a systematic review. The first is its methodologi-
cal quality, which is an assessment of how well the system-
atic review was conducted (literature search, pooling of
data, etc.). The second is its quality of reporting, which is an
assessment of how well its systematic reviewers have
reported their methodology and findings. Separate tools
were used to assess each quality area to obtain a compre-
hensive quality assessment. Assessors were sensitive to the
fact that although methodological quality and reporting
quality are intrinsically linked, a review may be strong in
either area and weak in the other. It was also recognized that
poor reporting makes it difficult to assess the methodologi-
cal quality of a review.
Our objective was to review both the methodological and
reporting quality of all published Cochrane systematic mus-
culoskeletal reviews. This review should serve as a baseline,
enabling the CMSG to measure improvement in both the
methodological and the reporting quality of its reviews over
time.
MATERIALS AND METHODS
Choosing the assessment instruments. A review of published scales and
checklists was performed to inventory the instruments available for assess-
ing the quality of systematic reviews. Each item of a scale is scored numer-
ically, and individual numerical scores are combined to generate an overall
quality score. To be considered a scale, an instrument should be able to
measure across a continuum. On the other hand, a checklist provides an esti-
mate of the overall quality of a review by using itemized criteria to assess
individual aspects of reviews and facilitate their qualitative comparisons.
Individual checklist items do not have numerical scores attached to them.
A literature search was conducted using Medline from January 1966 to
February 1999 to identify all published quality assessment instruments.
Three independent searches were completed using the following keywords:
metaanalysis, review literature, systematic or quantitative or methodologic
review, overview, review, information synthesis, integrative research
review, guideline, checklist, tool, scoring, scale, clinimetric, quality, criti-
cal reading, methodology, and Medline. The “related articles” function was
also used14.
Twenty-four assessment instruments were found, including 21 check-
lists and 3 scales. The 2 instruments selected were a methodological assess-
ment tool that had been rigorously developed by Oxman and Guyatt,
known as the Overview Quality Assessment Questionnaire (OQAQ)15,16
quality of reporting tool (Quality of Reporting of Meta-analysis
(QUOROM)) developed by consensus17.
The Overview Quality Assessment Questionnaire. The specified purpose of
the OQAQ15 is to evaluate the scientific quality (i.e., adherence to scientif-
ic principles) of systematic reviews published in medical literature. It is not
designed to measure literary quality, importance, relevance, originality, or
any other esthetic or philosophical attribute of reviews.
The scale is divided into 9 areas (Table 1). Question 10, the final question
of the scale, requires each assessor to rate the overall scientific quality of each
report. Possible scores on question 10 range from 1 to 7. This global question
is answered based on how well the review scored on the first 9 questions16.
The Quality of Reporting of Meta-analysis (QUOROM) Checklist. The only
tool found that was designed to assess the reporting quality of systematic
reviews was the Quality of Reporting of Meta-analysis17 statement consist-
ing of a checklist and flow diagram. This checklist of standards for the
reporting of metaanalyses describes the preferred way to present the
Abstract, Introduction, Methods, Results, and Discussion sections of a
report of metaanalysis. The checklist includes 18 items (Table 2). It
requires authors of reviews to include a flow diagram that provides infor-
mation about the number of studies identified, included, and excluded, and
the reasons for excluding them.
The OQAQ and the QUOROM statement were found to be the instru-
ments of choice for assessing the quality of systematic reviews.
Literature. The study examined all published CMSG systematic reviews
from the Cochrane Database of Systematic Reviews of the Cochrane
Library, Issue 4, 20025.
Pilot testing. Two assessors (DF, BS) conducted a pilot study to test the 2
quality assessment tools. As recommended by Glass, et al7, agreement
among assessors was maximized through consensus training involving dis-
cussion among reviewers. All inconsistencies identified were discussed and
resolved during weekly meetings, and assessments were revised after con-
sensus was reached. The pilot exercise was conducted to achieve a high
level of interrater agreement. It was decided that an interclass correlation
coefficient (ICC) of 0.60 would be the lowest acceptable level of interrater
reliability. An ICC was calculated for a subset of questions on the OQAQ,
and the ICC results > 0.60 were eventually obtained. However, initially
there was less agreement between reviewers on the questions on the
OQAQ. Therefore, each item was reviewed and discussed in detail, with
agreement being reached on its scoring in cases where there had been dis-
agreement. This pilot was repeated until an ICC > 0.60 was achieved. Final
ICC of 0.81 (95% CI 0.74–0.89), 0.83 (0.77–0.90), and 0.88 (0.85–0.93)
were obtained for the questions on the OQAQ. Minor refinements were
incorporated into the interpretation of the scale, permitting a greater degree
of precision when performing assessments. A kappa test was also per-
formed on a subset of the CMSG reviews. The kappa was 0.321 (95% CI
0.136–0.498) prior to discussion and consensus. Additional pilot testing
improved the level of agreement slightly 0.420 (95% CI 0.322–0.514).
Data analysis. Data were extracted using prepared forms that included all
the items of both quality instruments. All included reviews were assessed
using this structured format. Frequencies were provided on all items of both
instruments using SPSS 12.0. Percentages were recorded, along with an
overall mean score and confidence intervals.
Main study. The quality of all 57 included systematic reviews18-74 was
assessed by 2 independent reviewers using the 2 selected tools, with a third
reviewer available when needed to reach a consensus (GW). One reviewer
(DF) had been involved with the Cochrane Collaboration for two and a half
years, and continues to work as a reviewer with the Acute Respiratory
Infections Review Group in Brisbane, Australia. The second reviewer (BS)
had been involved with the CMSG over the previous 10 years and was a
coauthor of some of the reviews.
RESULTS
Using the OQAQ, the mean overall scientific quality of the
57 Cochrane Musculoskeletal Reviews evaluated was mean
5.02 (95% CI 3.71–6.32). The scores for each item were of
10 The Journal of Rheumatology 2006; 33:1
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similar quality (Table 1). Of the 10 items making up the
scale, the Cochrane musculoskeletal systematic reviews
scored poorly on items 2 and 4: 63% of CMSG systematic
reviews reported whether the search strategy for the evi-
dence was reasonably comprehensive (item 2) and 53%
reported whether study selection bias was avoided (item 4).
All CMSG systematic reviews reported the criteria used for
deciding which studies to include in the overview (item 3)
and combined the findings of the relevant studies appropri-
ately relative to the primary question addressed (item 8).
The methods used for combining studies were reported in
95% of the reviews (item 7), while 97% of CMSG reviews
reported the criteria used for assessing the validity of includ-
ed studies (item 5) and drew conclusions that were support-
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Table 1. Scores for Cochrane musculoskeletal group (CMSG) systematic reviews from the Overview Quality Assessment Questionnaire (OQAQ).
Questions Yes, n (%) Partially or No, n (%)
can’t tell, n (%)
Item 1 1. Were the search methods used to find evidence reported? 50 (88) 3 (5) 4 (7)
Item 2 2. Was the search strategy for evidence reasonably comprehensive? 36 (63) 3 (5) 18 (32)
Item 3 3. Were the criteria used for deciding which studies to include in the overview reported? 57 (100) 0 (0) 0 (0)
Item 4 4. Was bias in the selection of studies avoided? 30 (53) 23 (40) 4 (7)
Item 5 5. Were the criteria used for assessing the validity of the included studies reported? 55 (97) 2 (3) 0 (0)
Item 6 6. Was the validity of all the studies referred to in the text assessed using appropriate criteria 41 (72) 4 (7.0) 12 (21)
(either in selecting studies for inclusion or in analyzing the studies that are cited)?
Item 7 7. Were the methods used to combine the findings of the relevent studies (to reach a 54 (95) 1 (2) 2 (3.5)
conclusion) reported?
Item 8 8. Were the findings of the relevent studies combined appropriately relative to the primary 57 (100) 0 (0) 0 (0)
question the overview addressed?
Item 9 9. Were the conclusions made by the author(s) supported by the data and/or analysis 55 (97) 1 (2) 1 (2)
reported in the overview?
Item 10 10. How would you rate the scientific quality of this overview? 5.02, 95% CI 3.71, 6.32
Table 2. Scores for Cochrane musculoskeletal group (CMSG) systematic reviews from Quality of Reporting of Meta-analysis (QUOROM).
Questions Yes, n (%) No, n (%)
Item 1 Does the title identify the report as a metaanalysis (or systematic review) of randomized trials? 3 (5) 54 (95)
Item 2 Is the abstract in a structured format? 56 (98) 1 (2)
Item 3 Do the objectives describe the clinical question explicitly? 56 (98) 1 (2)
Item 4 Are the data bases (i.e., list) and information sources described? 55 (96.5) 2 (3.5)
Item 5 Are the selection criteria (population, intervention, outcome, and study design), methods for validity assessment, 47 (82) 10 (18)
data abstraction, study characteristics, and quantitative data synthesis described in sufficient detail to permit replication?
Item 6 Is there a description of the main results? 49 (86) 8 (14)
Item 7 Are the conclusions presented? 57 (100) 0 (0)
Item 8 Is the clinical, biologic rationale for the intervention and rationale for the review provided? 54 (95) 3 (5)
Item 9 Were the information sources in detail (e.g., databases, registers, personal files, expert informants, agencies, 52 (91) 5 (9)
hand-searching), and any restrictions (years considered, publication status, language of publication) provided?
Item 10 Were the inclusion and exclusion criteria (defining population, intervention principal outcomes, and study design) 57 (100) 0 (0)
presented?
Item 11 Were the criteria and process used (e.g., masked conditions, quality assessment and their findings) in the validity 57 (100) 0 (0)
assessment reported?
Item 12 Was the process provided (e.g., completed independently, in duplicate)? 50 (88) 7 (12)
Item 13 Were the type of study design, participants’ characteristics, details of intervention, outcome definitions, and 56 (98) 1 (2)
how clinical heterogeneity was assessed reported?
Item 14 Were the principal measures of effect (e.g., relative risk), method of combining results (statistical testing and 53 (93) 4 (7)
confidence intervals), handling of missing data, how statistical heterogeneity was assessed, a rationale for any a 
priori sensitivity and subgroup analyses, and any assessment of publication bias reported?
Item 15 Was a metaanalysis profile summarizing trial flow provided? 0 (0) 57 (100)
Item 16 Were the descriptive data for each trial presented? 57 (100) 0 (0)
Item 17 Was the agreement on the selection and validity assessment reported? Were the simple summary results (for 56 (98) 1 (2)
each treatment group in each trial, for each primary outcome), and data needed to calculate effect sizes and 
confidence intervals in intention-to-treat analyses (e.g., 2 × 2 tables of counts, means and standard deviations, 
proportions) reported?
Item 18 Were a summarization of the key findings, discussion of clinical inferences based on internal and external validity, 47 (82) 10 (18)
interpretation of the results in light of the totality of available evidence, description of potential biases in the review 
process (e.g., publication bias), and suggestion of a future research agenda presented?
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ed by the data and/or analysis reported in the overview (item
9). Eighty-eight percent of the reviews reported the search
methods used to find evidence (item 1). However, only 72%
reported whether the validity of all the studies referred to in
the text was assessed using appropriate criteria (either in
selecting studies for inclusion or in analyzing the studies
that are cited) (item 6).
Scores on individual QUOROM items ranged from 5.0%
(item 1) to 100% (items 7, 10, 11, 16) (Table 2). Only 5% of
CMSG reviews identified the review as a metaanalysis or sys-
tematic review of randomized trials in their title (item 1).
Almost all CMSG reviews had an abstract with a structured
format (item 2) and included objectives (item 3) and data
sources (item 4) in the abstract. Items on which they were less
likely to report adequately were results (item 6) and selection
criteria (item 5) (i.e. population, intervention, outcome, study
design, methods for validity assessment, data abstraction,
study characteristics, and quantitative data synthesis).
Almost 90% of the reviews described their method of
data abstraction (item 12), while no review provided a flow
chart for the included and excluded studies (item 15).
More than half the CMSG reviews received a rating of
“adequate” on 50% or more of the 10 OQAQ quality items.
On the overall quality item (range 0–7) (item 10), the CMSG
reviews scored relatively well, with only minor flaws identi-
fied [mean 5.02 (95% CI 3.71–6.32)] (Table 1). Of the 18
QUOROM items, the CMSG systematic reviews scored
more than 50% on all but 2 of the items (items 1 and 15).
One item (18) was noted as being more difficult to assess
and certainly needs further exploration [i.e., the summariza-
tion of the key findings, discussion of clinical inferences
based on internal and external validity, interpretation of the
results in light of the totality of available evidence, descrip-
tion of potential biases in the review process (e.g., publica-
tion bias), and suggestion of a future research agenda pre-
sented]. 
Documenting the flow of included and excluded studies
and summarizing the results are 2 areas needing improve-
ment in reporting.
DISCUSSION
Assessments made using both quality instruments indicated
that the quality of Cochrane musculoskeletal systematic
reviews was good, although minor flaws were observed.
This is important to users of CMSG reviews, as it provides
assurance that their results are relatively reliable. Although
their methodological quality and quality of reporting were
found to be fair to good, there is room for improvement. For
example, it might be feasible to develop specific guidelines
for reporting protocols and improve on reporting search
results, and documentation of the flow of studies.
The quality of systematic reviews requires examination
in order to substantiate the claim that they are the best evi-
dence available to clinicians, health policymakers, and con-
sumers. The use of assessment tools to structure peer review
systems can encourage quality improvement in systematic
reviews. The Cochrane Collaboration has begun to achieve
this objective through continual peer review of protocols,
reviews, and updated reviews from the analytical process
through to the report. The use of evidence-based criteria
such as the QUOROM statement can contribute to the
improvement of reporting quality over time by establishing
consistent guidelines for the conduct of systematic reviews.
At least 2 studies have addressed improvement or lack of
improvement over time. A review of 86 English-language
metaanalyses assessed every report on 14 items from 6 con-
tent areas believed to be critical in the conduct and reporting
of metaanalyses. These items included study design, com-
binability, control of bias, statistical analysis, sensitivity
analysis, and problems of applicability. They found that only
24 of the 86 (28%) metaanalyses addressed all 6 content
areas75. This survey was updated in 1992 with little change
in the results76. A similar study by the authors of this paper
showed that the quality of systematic reviews does improve
over time, but that the differences on specific items remain
variable77. A comparison of Cochrane versus paper-based
reviews revealed similar results78.
Inadequate reporting79,80-82 is a significant impediment
to the assessment of the quality of systematic reviews!
Essential criteria may be met in a given study without being
adequately reported in a review. In such a case, a study of
high quality may appear to be poor in a review. It may be
inaccurate to assume that items not included in a systematic
review were missing in the study it reviews, but this is what
users of systematic reviews are likely to do. Assessors of a
systematic review may invest the time and effort required to
obtain additional data directly from the investigators who
conducted the systematic review, but ordinary readers can-
not reasonably be expected to do so.
The ongoing use of the quality of reporting check-
lists6,80–82 is to be encouraged, because it will facilitate
assessment of study validity by ensuring a high level of con-
gruence between the quality of individual studies and their
depiction in systematic reviews. Such an improvement in
the quality of reporting of reviewed studies will serve to
make systematic reviews more accurate, reliable, persua-
sive, and useful to those who depend on them.
We tried to address the issue of potential conflict of inter-
est by inviting someone from outside the Musculoskeletal
group who would be willing to work with the team on a vol-
untary basis to carry out this study, a common practice for
Cochrane work, especially methods work. One of the main
reviewers of the studies is from Brisbane, Australia, and had
worked with the Respiratory Airways group for about 3 years.
He is very well informed of the format of a Cochrane review.
The authors felt that because he was not involved in any of the
CMSG reviews he would be considered a nonbiased review-
er. We believe this will negate any potential biases.
12 The Journal of Rheumatology 2006; 33:1
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2006. All rights reserved.
Although the 2 instruments used in this study proved use-
ful, the challenges that had to be overcome in applying them
clearly demonstrated the need for better measurement
instruments. Both instruments proved to be difficult to
apply; the main problem encountered was a lack of pub-
lished guidance on their application. It was only after 3
rounds of pilot testing and resolution of several questions
that arose concerning the application of the OQAQ assess-
ment tool that the assessors were ready to apply it.
Moreover, while using this scale, reviewers continued to
encounter difficulties with its application. Although the
QUOROM checklist was rather long and time-consuming to
apply, it was accompanied by more detailed directions
regarding its use.
One additional item that was not addressed adequately
because the measurement tool does not address this well is
the inferences based on the results of the systematic reviews.
More work is needed in this area.
The statistical analysis revealed that the reliability was
poor to fair. There may be several explanations for this.
First, the relative magnitude of the kappa value (i.e., the pro-
portion of agreement beyond that expected by chance alone)
is difficult to interpret. In the pilot test, the kappa values
were categorized and labeled as suggested by Fleiss83, but
this classification is purely arbitrary. Kappa coefficient is a
popular measure for chance-corrected nominal scale agree-
ment between 2 raters. Future methodological work must
include alternative options for calculating agreement among
raters, such as exploring Bayesian inferences.
This study found that the overall quality of reports of
Cochrane musculoskeletal systematic reviews was generally
good, although there was room for improvement. Areas in
particular that need special attention include the title and
protocol, documentation of the flow of the studies, and
inferences made by the conclusions. A recent study reported
that the methods for assessment of methodological quality of
systematic reviews are still in their infancy and there is sub-
stantial room for improvement84.
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